MicroIslet to Present at Rodman & Renshaw Global Healthcare Conference
May 11 2006 - 1:03PM
PR Newswire (US)
SAN DIEGO, May 11 /PRNewswire-FirstCall/ -- MicroIslet, Inc.
(AMEX:MII), a biotechnology company engaged in the research,
development and commercialization of patented technologies in
transplantation therapy for people with insulin-dependent diabetes,
announced today its scheduled presentation at Rodman &
Renshaw's 3rd Annual Global Healthcare Conference on Monday, May
15, at 5:25 p.m. local time in Monte Carlo, Monaco. This conference
will be held at the Le Meridien Beach Plaza Hotel in Monte Carlo.
John F. Steel IV, MicroIslet's Director of Corporate Communications
and a member of its Board of Directors, will update conference
attendees on preclinical advances in the Company's proprietary
approach to treating insulin-dependent diabetes through minimally
invasive transplantation of microencapsulated, insulin-producing
porcine islets. This therapeutic approach is designed to replace
the need for frequent insulin injections and blood monitoring on
the part of insulin-dependent diabetics. MicroIslet enjoys
exclusive access to the Mayo Foundation's designated pathogen-free
pig facility for the treatment of diabetes, providing the Company
with an existing supply of suitable cells. Further, the Company's
proprietary microencapsulation techniques are designed to obviate
the need for immunosuppressive therapy to prevent the recipient's
immune rejection of the transplanted insulin-producing tissues.
About MicroIslet MicroIslet is a biotechnology company engaged in
the research, development, and commercialization of patented
technologies in the field of transplantation therapy for people
with insulin-dependent diabetes. MicroIslet's patented islet
transplantation technology, exclusively licensed from Duke
University, includes methods for isolating, culturing,
cryopreservation, and immuno-protection (microencapsulation) of
islet cells. MicroIslet is working to develop and commercialize a
first product, called MicroIslet-P(TM), a microencapsulated porcine
islet cell suspension that will be used for transplantation in
patients with insulin-dependent diabetes. Additional information
about MicroIslet can be found at http://www.microislet.com/. Except
for the historical information contained herein, the matters set
forth in this press release, including the implication and
interpretation of preliminary data, the expectation of development
of new therapeutic products and the impact of MicroIslet's products
on diabetes patients, are forward-looking statements within the
meaning of the "safe harbor" provisions of the Private Securities
Litigation Reform Act of 1995. These forward-looking statements are
subject to risks and uncertainties that may cause actual results to
differ materially, including MicroIslet's ability to continue as a
going concern, the risks and uncertainties inherent in medical
treatment discovery, development and commercialization, the risks
and uncertainties associated with MicroIslet's early stage
xenotransplantation technologies, the risks and uncertainties of
governmental approvals and regulation, dependence on the Mayo
Foundation for Medical Education and Research as a sole source
supplier of animal parts for pre-clinical and clinical studies,
MicroIslet's need to raise substantial additional capital to
proceed through human clinical trials and bring any product to
market, the risks that MicroIslet's competitors will develop or
market technologies or products that are more effective or
commercially attractive than MicroIslet's products, and other risks
detailed from time to time in MicroIslet's most recent filings with
the Securities and Exchange Commission. These forward-looking
statements speak only as of the date hereof. MicroIslet disclaims
any intent or obligation to update these forward-looking
statements. For more information, please visit our Web site at
http://www.microislet.com/. For further information, contact: Kevin
A. Hainley, MicroIslet, Inc. 858-657-0287, Sean Collins, Partner
CCG Investor Relations & Strategic Communications 310-231-8600
ext. 202 ISIN US59507Q1067 DATASOURCE: MicroIslet, Inc. CONTACT:
Kevin A. Hainley of MicroIslet, Inc., +1-858-657-0287, ; or Sean
Collins, Partner, CCG Investor Relations & Strategic
Communications, +1-310-231-8600, ext. 202, for MicroIslet, Inc. Web
site: http://www.microislet.com/
Copyright
Microislet (AMEX:MII)
Historical Stock Chart
From May 2024 to Jun 2024
Microislet (AMEX:MII)
Historical Stock Chart
From Jun 2023 to Jun 2024